MBIO Stock Overview
A clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases.
| Snowflake Score | |
|---|---|
| Valuation | 0/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 1/6 |
| Dividends | 0/6 |
Mustang Bio, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$0.22 |
| 52 Week High | US$2.11 |
| 52 Week Low | US$0.13 |
| Beta | 1.95 |
| 11 Month Change | -20.78% |
| 3 Month Change | -55.80% |
| 1 Year Change | -88.97% |
| 33 Year Change | -99.36% |
| 5 Year Change | -99.49% |
| Change since IPO | -99.85% |
Recent News & Updates
Recent updates
Mustang Bio: This Horse May Gallop Still
Sep 23Is Mustang Bio, Inc. (NASDAQ:MBIO) Trading At A 46% Discount?
Aug 09
Mustang Bio: The Market Is Missing This Opportunity
May 03Will Mustang Bio (NASDAQ:MBIO) Spend Its Cash Wisely?
Dec 29Mustang Bio: Remains Underfollowed Despite Moving Closer To Pivotal Studies
Sep 14Mustang Bio (MBIO) EHA Investor Presentations - Slideshow
Jun 18Mustang Bio jumps 7% on encouraging MB-106 safety and efficacy data in blood cancers
Jun 11Checking Back In On Mustang Bio
May 26FDA accepts Mustang Bio's MB-106 application in cancer
May 10Here's Why We're Watching Mustang Bio's (NASDAQ:MBIO) Cash Burn Situation
Mar 22What Type Of Shareholders Own The Most Number of Mustang Bio, Inc. (NASDAQ:MBIO) Shares?
Feb 23Mustang Bio, Inc.'s (NASDAQ:MBIO) Intrinsic Value Is Potentially 25% Below Its Share Price
Jan 28
Shareholder Returns
| MBIO | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -5.0% | -1.6% | -0.7% |
| 1Y | -89.0% | 17.6% | 32.5% |
Return vs Industry: MBIO underperformed the US Biotechs industry which returned 17.6% over the past year.
Return vs Market: MBIO underperformed the US Market which returned 32.5% over the past year.
Price Volatility
| MBIO volatility | |
|---|---|
| MBIO Average Weekly Movement | 13.4% |
| Biotechs Industry Average Movement | 9.9% |
| Market Average Movement | 6.4% |
| 10% most volatile stocks in US Market | 14.9% |
| 10% least volatile stocks in US Market | 3.2% |
Stable Share Price: MBIO's share price has been volatile over the past 3 months compared to the US market.
Volatility Over Time: MBIO's weekly volatility has decreased from 69% to 13% over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2015 | 80 | Manny Litchman | www.mustangbio.com |
Mustang Bio, Inc., a clinical-stage biopharmaceutical company, focuses on translating medical breakthroughs in cell and gene therapies into potential cures for hematologic cancers, solid tumors, and rare genetic diseases. Its pipeline focuses on gene therapy programs for rare genetic disorders, chimeric antigen receptor (CAR) engineered T cell (CAR T) therapies for hematologic malignancies, and CAR T therapies for solid tumors. The company develops MB-117 and MB-217, a gene therapy program for X-linked severe combined immunodeficiency, a rare genetic immune system condition in which affected patients do not live beyond infancy without treatment.
Mustang Bio, Inc. Fundamentals Summary
| MBIO fundamental statistics | |
|---|---|
| Market cap | US$8.27m |
| Earnings (TTM) | -US$32.06m |
| Revenue (TTM) | n/a |
0.0x
P/S Ratio-0.3x
P/E RatioIs MBIO overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| MBIO income statement (TTM) | |
|---|---|
| Revenue | US$0 |
| Cost of Revenue | US$0 |
| Gross Profit | US$0 |
| Other Expenses | US$32.06m |
| Earnings | -US$32.06m |
Last Reported Earnings
Jun 30, 2024
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.86 |
| Gross Margin | 0.00% |
| Net Profit Margin | 0.00% |
| Debt/Equity Ratio | 0% |
How did MBIO perform over the long term?
See historical performance and comparison